LAIR-1, Human, mAb NKTA255
The monoclonal antibody clone NKTA255 recognizes human leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1). The LAIR family consist of at least two members; LAIR-1 (CD305) and LAIR-2 (CD306). To date, several splice variants of LAIR-1 have been identified. LAIR-1 is an inhibitory receptor expressed on most immune cells, like NK cells, T- & B-cells, monocytes, DCs, megakaryocytes, eosinophils, basophils, and mast cells. Especially the expression on pDCs is high. The main ligand of LAIR proteins is collagen. LAIR-1 is a transmembrane receptor with a single extracellular Ig-like domain, a transmembrane region and a cytoplasmic tail. This tail consist of two immunoreceptor tyrosine-based inhibition motif (ITIM) domains, which are responsible for its immunomodulating action. After cross-linking, the tyrosines in the ITIMs become phosphorylated which is required for inhibition of cellular activation. By shedding a soluble variant of the protein arises. sLAIR-1 can be found in healthy individuals and can be used as a marker of lymphocyte activation. sLAIR-1 has been found among others in serum, urine, amniotic fluid, and synovial fluid. Besides collagen, a few other ligands are described like Complement C1q, MBL, and SP-D. Complement activation of the classical pathway is controlled by C1q. By binding of LAIR-1 to C1q, pathway initiation is hampered leading to diminished complement related phagocytosis and immune regulation.
The protein has been associated with several (auto-) immune diseases. In rheumatoid arthritis expression is decreased on CD4+ T-cells and high in CD14+ monocytes synovial macrophages. Also in SLE lower levels of LAIR-1 has been found on pDCs. sLAIR-1 might be an indicator of the immune response after virus infection or organ transplants. LAIR-1 modulates apoptosis and cytokine secretion in THP-1 cells.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA